Literature DB >> 10601567

Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review).

L J Martin1, A C Price, A Kaiser, A Y Shaikh, Z Liu.   

Abstract

Amyotrophic lateral sclerosis (ALS), also referred to as motor neurone disease, is a fatal neurological disease that is characterized clinically by progressive muscle weakness, muscle atrophy, and eventual paralysis. The neuropathology of ALS is primary degeneration of upper (motor cortical) and lower (brainstem and spinal) motor neurons. The amyotrophy refers to the neurogenic atrophy of affected muscle groups, and the lateral sclerosis refers to the hardening of the lateral white matter funiculus in spinal cord (corresponding to degeneration of the corticospinal tract) found at autopsy. Because the mechanisms for the motor neuron degeneration in ALS are not understood, this disease has no precisely known causes and no effective treatments. Very recent studies have identified that the degeneration of motor neurons in ALS is a form of apoptotic cell death that may occur by an abnormal programmed cell death (PCD) mechanism. In order to treat ALS effectively, we need to understand the mechanisms for motor neuron apoptosis more completely. Future studies need to further identify the signals for PCD activation in neurons as they relate to the pathogenesis of ALS and to clarify the molecular pathways leading to motor neuron apoptosis in animal and cell culture model systems. These studies should lead to a better understanding of motor neuron death and to the design of new therapeutic experiments critical for the future treatment of ALS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10601567     DOI: 10.3892/ijmm.5.1.3

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  27 in total

1.  Delayed neurodegeneration in neonatal rat thalamus after hypoxia-ischemia is apoptosis.

Authors:  F J Northington; D M Ferriero; D L Flock; L J Martin
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 2.  Mechanisms of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  S Cluskey; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

Review 3.  Mitochondrial pathobiology in ALS.

Authors:  Lee J Martin
Journal:  J Bioenerg Biomembr       Date:  2011-12       Impact factor: 2.945

4.  Transplantation of human bone marrow stem cells into symptomatic ALS mice enhances structural and functional blood-spinal cord barrier repair.

Authors:  Svitlana Garbuzova-Davis; Edward Haller; Stephanie Navarro; Tony E Besong; Kayla J Boccio; Surafuale Hailu; Mohammed Khatib; Paul R Sanberg; Stanley H Appel; Cesario V Borlongan
Journal:  Exp Neurol       Date:  2018-08-30       Impact factor: 5.330

5.  DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis.

Authors:  Arif Y Shaikh; Lee J Martin
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

6.  Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander
Journal:  Neurobiol Dis       Date:  2013-03-26       Impact factor: 5.996

7.  Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models.

Authors:  Eun Jin Yang; Jing Hua Jiang; Sang Min Lee; Sun Choel Yang; Hye Suk Hwang; Myeong Soo Lee; Sun-Mi Choi
Journal:  J Neuroinflammation       Date:  2010-10-15       Impact factor: 8.322

Review 8.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

9.  Role of nitric oxide and cyclic GMP in glutamate-induced neuronal death.

Authors:  C Montoliu; M Llansola; P Monfort; R Corbalan; I Fernandez-Marticorena; M L Hernandez-Viadel; V Felipo
Journal:  Neurotox Res       Date:  2001-04       Impact factor: 3.911

Review 10.  CD 4+ T cells in the pathobiology of neurodegenerative disorders.

Authors:  Xiuyan Huang; Ashley D Reynolds; R Lee Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2009-05-12       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.